<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Driving restrictions in patients with an implantable cardioverter-defibrillator</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Driving restrictions in patients with an implantable cardioverter-defibrillator</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Driving restrictions in patients with an implantable cardioverter-defibrillator</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kapil Kumar, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N A Mark Estes, III, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The implantable cardioverter-defibrillator (ICD) has been instrumental in improving survival in patients resuscitated from ventricular fibrillation or unstable ventricular tachycardia (ie, secondary prevention of sudden cardiac death). There are compelling data that the ICD is also effective in the primary prevention of sudden cardiac death (SCD) in select high-risk patients. Since many patients with an ICD may be healthy enough to drive an automobile, this topic will review the concerns regarding the risk of ventricular arrhythmias and ICD shocks in this patient population while driving. (See  <a class="medical medical_review" href="/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a> and  <a class="medical medical_review" href="/d/html/963.html" rel="external">"Overview of sudden cardiac arrest and sudden cardiac death"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INCREASED RISK WITH DRIVING</span><span class="headingEndMark"> — </span>For patients with ICDs, driving could lead to losing control of the vehicle if there are symptomatic ventricular arrythmias or ICD shocks. Loss of vehicle control not only poses a risk to the patient, but also to other occupants of the vehicle and persons outside of the vehicle. The extension of risk to others makes this issue a public health concern. Data regarding the risks associated with driving with an ICD are primarily retrospective, with no prospective trials that have randomized patients to driving with or without restrictions. Recommendations are based primarily on expert opinion and public policy. </p><p class="headingAnchor" id="H3"><span class="h2">Causes of accidents</span><span class="headingEndMark"> — </span>Both ventricular arrhythmias and ICD-delivered shock therapies can interfere with driving and lead to accidents. In patients with ICDs, causes of accidents include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sudden cardiac death </strong>– Although ICDs have been shown to improve survival, they do not entirely eliminate the risk of sudden cardiac death (SCD). Data from major trials indicate that the residual rate of SCD among patients who receive an ICD for secondary prevention is one to two percent per year [<a href="#rid1">1-3</a>]. Similar or slightly lower SCD rates have been reported in major primary prevention trials [<a href="#rid4">4-6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syncope </strong>– Syncope may occur due to arrhythmic and nonarrhythmic causes in ICD recipients. Even rapid treatment of a ventricular arrhythmia by an ICD may not protect against driving impairment, since syncope or altered states of consciousness can still occur. In the MADIT-RIT study, which included 1500 patients who received a primary prevention ICD and who were followed for an average of 1.4 years, 64 patients (4.3 percent) experienced syncope, with similar frequency regardless of the programmed device settings [<a href="#rid7">7</a>]. (See <a class="local">'Syncope'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transient incapacitation from the shock </strong>– Even if therapy is successful and the patient remains conscious, the discomfort from an ICD discharge, either appropriate or inappropriate, may startle or briefly incapacitate the patient and disrupt safe motor vehicle operation.</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Overall incidence of ventricular arrhythmias and ICD shocks</span><span class="headingEndMark"> — </span>A higher incidence of ventricular arrhythmias and ICD shocks increases the likelihood of that an incident may occur during driving.</p><p class="headingAnchor" id="H5"><span class="h3">In patients treated for secondary prevention</span><span class="headingEndMark"> — </span>Data on the incidence of recurrent ventricular arrhythmias and ICD therapies among patients treated with an ICD for secondary prevention comes primarily from studies performed in the 1990s and early 2000s. As such, estimates of recurrent arrhythmia from those trials are presumably higher than what is seen in contemporary practice; this likely reflects the impact of contemporary medical therapy and ICD programming strategies, which appear to significantly reduce the rates of arrhythmias and inappropriate device therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>In the AVID trial, among the 449 patients assigned to ICD therapy, 35 percent of patients had an arrhythmic event (arrhythmic death, sustained ventricular arrhythmia, shock, or antitachycardia pacing) at three months, 53 percent had an event at one year, and 68 percent at two years [<a href="#rid8">8</a>]. First shocks or antitachycardia pacing after the second year were uncommon.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among a cohort of 256 patients who received a subcutaneous ICD (S-ICD) for secondary prevention and who were followed for an average of 21 months, 12 percent of patients received an appropriate ICD shock [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Danish Pacemaker and ICD Register, 4580 patients with ICDs placed for secondary prevention were followed for an average of 3.6 years [<a href="#rid10">10</a>]. Thirty percent experienced appropriate ICD therapies, of which 16.8 percent were ICD shocks, and 4.6 percent of patients had an inappropriate ICD shock. There was a reduction in appropriate (28.2 to 7.9 per 100 person-years) and inappropriate (10 to 1 per 100 person-years) ICD therapy over the study period 2007 to 2016.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study of patients with ICD for secondary prevention is the DREAM-ICD-II Study [<a href="#rid11">11</a>]. This study observed patients from Canada from 2016 to 2020. The incidence of recurrent ventricular arrhythmia was greatest during the first three months following ICD implantation (34.4 percent) and decreased over time to 10.6 percent between months 3 and 6 and 11.7 percent between months 6 and 12. The authors also observed that the cumulative rate of sudden incapacitation resulting from syncope was 1.8 percent during the first 90 days after ICD insertion and then reduced to 0.4 percent between three to six months.</p><p></p><p>Among patients treated with an ICD for secondary prevention, single device therapy has an increased risk of additional events. In one study, the mean time to first ICD therapy was 138 days; among those with a first event, the mean time to second ICD therapy was only 66 days [<a href="#rid12">12</a>]. Patients with an initial ICD therapy had a 79 percent likelihood of another ICD therapy within one year.</p><p>Patients who do not have an ICD therapy within the first year appear to have a lower, but still appreciable, risk of future events [<a href="#rid13">13,14</a>]. One report, for example, identified 14 patients who had not received an appropriate shock at 24 months [<a href="#rid13">13</a>]. The actuarial risk of an appropriate shock in the next 24 months was still 29 percent.</p><p class="headingAnchor" id="H6"><span class="h3">In patients treated for primary prevention</span><span class="headingEndMark"> — </span>Patients receiving an ICD for primary prevention have a lower risk of ventricular arrhythmias when compared with those in whom an ICD was placed for secondary prevention. Patients with primary prevention ICDs have variable rates of ICD discharge, which may be influenced by ICD programming, underlying cardiac diagnosis, and other factors [<a href="#rid5">5,15-17</a>]. (See  <a class="medical medical_review" href="/d/html/113776.html" rel="external">"Implantable cardioverter-defibrillators: Optimal programming", section on 'Tachycardia therapies'</a>.)</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In the MADIT-RIT trial of 1500 patients with a primary prevention ICD placed between 2009 and 2011 who were randomly assigned to one of three ICD programming strategies, appropriate ICD therapy occurred in 12.4 percent over 1.4 years [<a href="#rid16">16</a>]. When compared with conventional programming, delayed therapy programming and high-rate programming reduced the risk of inappropriate and appropriate shocks without increasing the risk of death or syncope [<a href="#rid16">16,18</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 803 patients who had a primary prevention ICD placed between 2016 and 2019, the rate of ICD-delivered therapy (anti-tachycardia pacing or ICD shock) was 0.4 percent at 30 days, 1 percent at 90 days, and 1.7 percent at 180 days [<a href="#rid17">17</a>]. There were no episodes of syncope after six months of observation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 1111 patients with a low ejection fraction who underwent an S-ICD implant between 2015 and 2018 for primary prevention, 9 percent had received a shock at 18 months [<a href="#rid19">19</a>]. </p><p></p><p class="headingAnchor" id="H7"><span class="h3">Predictors of events</span><span class="headingEndMark"> — </span>A number of clinical features are associated with an increased risk of arrhythmic events and ICD therapies. These include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced left ventricular ejection fraction (LVEF) [<a href="#rid12">12,20,21</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New York Heart Association Functional Class III or IV heart failure [<a href="#rid12">12,21,22</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sustained monomorphic VT rather than VF as the presenting arrhythmia [<a href="#rid12">12,21</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of revascularization in patients with coronary heart disease [<a href="#rid12">12,21</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of beta blocker therapy after hospital discharge [<a href="#rid12">12,21</a>]</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Syncope</span><span class="headingEndMark"> — </span>When considering the risks associated with driving by patients with ICDs, the incidence of ventricular arrhythmias and ICD discharge are less important than the actual incidence of syncope during an arrhythmic event (since not all events lead to impaired consciousness). The incidence of syncope among patients treated with an ICD for secondary prevention ranges from 15 to 46 percent [<a href="#rid12">12,23-25</a>].</p><p>The frequency, causes of, and risk factors for syncope were evaluated in a review of 421 patients with an ICD for secondary prevention [<a href="#rid23">23</a>]. At a mean follow-up of 26 months, 62 had syncope (15 percent of all patients and 27 percent of those with recurrent ventricular arrhythmia). Syncopal episodes occurred in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Shortly after rapid and successful delivery of a first 34 joule shock; the mean ICD capacitor charge time was 9.4 sec (55 percent of syncopal episodes)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VT that was initially treated with antitachycardia pacing, which may then lead to acceleration of the VT after pacing (16 percent of episodes)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Incessant or clusters of VT (VT storm) (8 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure of a first shock (7 percent)</p><p></p><p>No cause could be identified in three patients.</p><p class="headingAnchor" id="H9"><span class="h3">Risk factors for syncope</span><span class="headingEndMark"> — </span>Several clinical features predict an increased likelihood of syncope in patients treated with an ICD, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Syncope during a prior episode of VT [<a href="#rid23">23,26</a>]. In one series, among ICD patients with syncope during a prior episode of VT, the median time to a first recurrent syncopal event was 376 days, suggesting that patients who present with syncope during VT are more likely to have syncope with recurrent episodes of VT, and the standard six-month driving restriction may be inadequate [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very rapid VT (cycle length less than 300 msec) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced LVEF [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic atrial fibrillation [<a href="#rid23">23</a>].</p><p></p><p>The authors suggested that these risk factors may be used to risk-stratify ICD patients for future syncopal events. In the study discussed above, overall actuarial survival free of syncope was 90, 85, and 81 percent at one, two, and three years after implantation; in comparison, event-free survival was better in patients with none of the above risk factors (96, 92, and 92 percent) [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H151029463"><span class="h2">Effect of therapy on recurrent ventricular arrhythmias</span><span class="headingEndMark"> — </span>In many patients with chronic ventricular tachycardia, ventricular tachyarrhythmias can be suppressed by antiarrhythmic medications and catheter ablation, thereby preventing syncope or ICD shocks. A meta-analysis suggests that <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> is the most effective antiarrhythmic medication for suppression of ventricular arrhythmia [<a href="#rid27">27</a>]. Amiodarone modestly reduced the incidence of SCD in patients with or without an ICD (relative risk 0.76; 95% CI 0.66-0.88) and was superior to other antiarrhythmics with low to moderate quality of evidence.</p><p>Catheter ablation of VT has emerged as an effective treatment modality in patients with a prior documented history of VT or VF. One of the first studies to demonstrate the ability of substrate-based VT ablation to reduce future ICD therapy was the SMASH-VT study [<a href="#rid28">28</a>]. Appropriate ICD therapy occurred in 12 percent of the patients randomized to ICD implantation plus catheter ablation versus 33 percent in the ICD-implantation-alone arm over a mean follow-up of 22.5 months. Other randomized studies have also shown superiority of VT ablation over antiarrhythmic drugs to minimize outcomes of composite endpoints, which included appropriate ICD therapy [<a href="#rid29">29,30</a>].</p><p>Given the relatively high recurrence of ventricular tachyarrhythmias and ICD shocks after antiarrhythmic medications or catheter ablation over the ensuing months, these therapies may not sufficiently reduce the risk of impairment while driving.</p><p class="headingAnchor" id="H12"><span class="h2">Inappropriate ICD shocks</span><span class="headingEndMark"> — </span>Inappropriate shocks, which may predispose to an accident by startling or briefly incapacitating the patient, occur less frequently with modern generations and contemporary programming of ICDs. Thus, patients who have inappropriate ICD therapies without loss of consciousness may not require restriction. Again, official recommendations vary according to location. </p><p>Examples of trials and studies that report the rate of inappropriate shocks include:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 1500 patients who received an ICD for primary prevention in MADIT-RIT (average follow up 1.4 years), the annual incidence of inappropriate shocks was only 2.9 percent. The main cause is supraventricular tachyarrhythmia, in particular atrial fibrillation with rapid ventricular response. Such patients may often receive multiple inappropriate shocks. Other causes of inappropriate shocks include electrical noise from conditions such as lead fracture or external electromagnetic interference and ICD. (See  <a class="medical medical_review" href="/d/html/989.html" rel="external">"Cardiac implantable electronic devices: Long-term complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 4089 patients, 417 patients (65 percent with a secondary prevention indication) experienced an inappropriate shock. Less than 1 percent of patients experienced an episode of syncope associated with the inappropriate shock. The estimated maximum annual risk of harm is calculated well below the established acceptable risk threshold of 5 in 100,000 [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 1111 patients with a low ejection fraction who underwent an S-ICD implant between 2015 and 2018 for primary prevention, 4.1 percent experienced an inappropriate shock at 18 months [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h1">INCIDENCE OF ICD SHOCKS WHILE DRIVING AND ACCIDENTS</span><span class="headingEndMark"> — </span>Although information regarding the general incidence of arrhythmic events and the risk factors for such events are useful, there is now increasing evidence that directly addresses the incidence of such events while driving.</p><p class="headingAnchor" id="H14"><span class="h2">ICD shocks while driving</span><span class="headingEndMark"> — </span>The incidence of ICD shocks associated with driving was assessed in an analysis from the TOVA study [<a href="#rid32">32</a>]. A total of 1,188 patients treated with an ICD for a range of primary and secondary prevention indications were followed for a median of 562 days. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>The estimated risk of an ICD shock within one hour of driving was one shock per 25,000 person-hours of driving.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The relative risk for ICD shocks for VT/VF within one hour of driving compared to other times was 2.24. However, the elevated risk was limited to the 30 minutes after driving (relative risk 4.46 compared to other times), rather than during the driving episode itself (relative risk 1.05 compared to other times).</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Accidents</span><span class="headingEndMark"> — </span>Among patients with an ICD, the rate of motor vehicle accidents is highest immediately following ICD implantation and then decreases over months to years. However, accidents are typically underreported and may not be properly attributed to an arrhythmia or ICD-delivered therapy, which leads to potentially inaccurate measurements of the rate and cause of accidents in this population. The following studies illustrate the range of findings: </p><p class="bulletIndent1"><span class="glyph">●</span>In a Danish registry study that included 2741 patients with an ICD implanted for any indication between 2013 and 2016, 0.2 percent of patients received a shock while driving, and there was one traffic accident [<a href="#rid33">33</a>]. The authors estimated that the risk of harm was 0.0002 percent per person-year of ICD therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 14,230 patients who received an ICD for any indication between 2008 and 2013 and who experienced at least one shock, the risk of harm while driving after the initial shock (as determined by a formula that estimates the annual risk to other road users posed by a driver with an ICD, assuming a probability of loss of consciousness with an ICD shock of 32 percent) was 12.5 events per 100,000 ICD recipients at one month and 2.7 events per 100,00 recipients at one year [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients enrolled in a trial of ICD placement for secondary prevention (AVID) between 1993 and 1997, 50 patients reported having at least one accident, and there were a total of 55 accidents during 1619 patient-years of follow-up after the resumption of driving (3.4 events per 100 patient-years) [<a href="#rid35">35</a>]. Of these accidents, 11 percent (0.4 events per 100 patient-years) were preceded by symptoms of arrhythmia.</p><p></p><p class="headingAnchor" id="H1058211592"><span class="h1">RECOMMENDATIONS OF OTHERS AND GOVERNMENT LAWS</span></p><p class="headingAnchor" id="H18"><span class="h2">Patients with an ICD placed for secondary prevention</span><span class="headingEndMark"> — </span>Guidelines for driving after an episode of sudden cardiac death (SCD) have been published by various professional societies and local governments [<a href="#rid36">36-39</a>]. The general approaches to driving restriction in 4 different regions are summarized in the table  (<a class="graphic graphic_table graphicRef120456" href="/d/graphic/120456.html" rel="external">table 1</a>) [<a href="#rid37">37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Noncommercial drivers are generally advised to not drive for the first six months postimplantation (first three months in the European Union), the time of greatest risk for recurrent events [<a href="#rid8">8</a>]. If there has been no discharge from the ICD during this period, driving can be resumed  (<a class="graphic graphic_table graphicRef120456" href="/d/graphic/120456.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If highway or long-distance travel is anticipated, patients should be encouraged to have an adult companion drive, and cruise control driving should be avoided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The six-month driving restriction <strong>restarts</strong> if an ICD discharge occurs with or without syncope.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For commercial drivers, the risk of harm to the public as a consequence of ICD discharge or syncope is much higher. As a result, it was recommended that all commercial driving be prohibited permanently after a life-threatening ventricular arrhythmia whether the patient is treated with an ICD or antiarrhythmic drugs.</p><p></p><p>Some patients with an ICD have frequent episodes of hemodynamically well-tolerated, asymptomatic VT that are consistently terminated (and without acceleration) by antitachycardia pacing. The guidelines recommend that decisions on noncommercial driving in such patients be made on a case-by-case basis.</p><p>However, some have considered these guidelines too conservative in light of subsequently published data and advances in the treatment of arrhythmia [<a href="#rid40">40</a>]. In a report from the AVID trial described above, 57 percent of patients resumed driving within three months; the rate of patient-reported accidents preceded by symptoms suggestive of an arrhythmia was only 0.4 percent per patient-year, which is less than the accident rate in the general driving population (0.7 percent per year) [<a href="#rid35">35</a>]. Patients in the AVID registry who were not randomized had similar clinical characteristics to those who were, suggesting that these observations can be generalized to all patients who would be eligible [<a href="#rid41">41</a>]. Reporting bias is a potential problem since patients may underreport accidents or near-accidents.</p><p>These observations have led to the suggestion that low-risk patients (LVEF &gt;40 percent, no persistent medical condition predisposing to recurrent arrhythmia, and no recurrent ventricular arrhythmia) can begin driving after three months [<a href="#rid40">40</a>].</p><p>The 1997 ESC guidelines reached similar conclusions  (<a class="graphic graphic_table graphicRef120456" href="/d/graphic/120456.html" rel="external">table 1</a>), although it was emphasized that, because of limited data, the recommendations do not represent practice standards [<a href="#rid38">38</a>]. Thus, clinical judgment should be considered with a given patient [<a href="#rid42">42,43</a>].</p><p>As noted above, patients with frequent ICD shocks for recurrent arrhythmia may benefit from antiarrhythmic drug therapy or catheter ablation. (See  <a class="medical medical_review" href="/d/html/972.html" rel="external">"Pharmacologic therapy in survivors of sudden cardiac arrest", section on 'Treatment of breakthrough arrhythmias'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Patients with an ICD placed for primary prevention</span><span class="headingEndMark"> — </span>The 2007 addendum to the AHA/NASPE guidelines provided the following driving recommendations  (<a class="graphic graphic_table graphicRef120456" href="/d/graphic/120456.html" rel="external">table 1</a>) for patients with ICDs implanted for primary prevention [<a href="#rid39">39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Noncommercial driving should be restricted for at least one week following ICD implantation. In the absence of symptoms potentially related to an arrhythmia, driving privileges thereafter should not be restricted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be instructed that impairment of consciousness is a possible future event.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have received an ICD for primary prevention who subsequently receive an appropriate therapy for VT or VF, especially with symptoms of cerebral hypoperfusion, should be managed according to the recommendations for patients with ICDs for secondary prevention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>These recommendations do not apply to the licensing of commercial drivers.</p><p></p><p>The ESC guidelines recommended no restriction for noncommercial driving, beyond the two-week restriction immediately following implantation to allow for wound healing, but total restriction for commercial driving when an ICD was implanted for primary prevention  (<a class="graphic graphic_table graphicRef120456" href="/d/graphic/120456.html" rel="external">table 1</a>) [<a href="#rid38">38,43</a>]. As in low-risk patients who receive an ICD for secondary prevention, resumption of driving may be safe after three months in patients who receive an ICD for primary prevention if they have had no sustained ventricular tachyarrhythmias [<a href="#rid40">40,44</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Patients with nonsustained arrhythmias but without an ICD</span><span class="headingEndMark"> — </span>The 1996 AHA/NASPE guidelines also made recommendations for driving in patients with ventricular tachyarrhythmias (nonsustained VT and idiopathic VT) not associated with loss of consciousness not treated with ICDs [<a href="#rid37">37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>No restrictions for either noncommercial or commercial driving for patients with nonsustained VT without impaired consciousness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Noncommercial driving should be restricted for three months and commercial driving for six months in patients with nonsustained VT and impaired consciousness or with idiopathic VT (ie, no apparent structural heart disease) without impaired consciousness. Driving must cease if there are disabling symptoms. Driving is only allowed after specialist assessment and satisfactory control of the arrhythmia. If there is an indication for an ICD, the respective rules apply. (See  <a class="medical medical_review" href="/d/html/965.html" rel="external">"Ventricular tachycardia in the absence of apparent structural heart disease"</a> and  <a class="medical medical_review" href="/d/html/916.html" rel="external">"Catecholaminergic polymorphic ventricular tachycardia"</a>.) </p><p></p><p class="headingAnchor" id="H22"><span class="h2">Governmental laws</span><span class="headingEndMark"> — </span>Legal restrictions on driving for patients with a history of cardiac arrhythmias, non-seizure syncope, and seizure syncope differ among local, regional, and national governments  (<a class="graphic graphic_table graphicRef120456" href="/d/graphic/120456.html" rel="external">table 1</a>), and there is generally no distinction between patients managed medically or with an ICD [<a href="#rid25">25,43</a>]. It has been estimated that, as of 1992, only about 30 percent of clinicians who implanted an ICD were aware of governmental regulations regarding driving [<a href="#rid45">45</a>]. Furthermore, among those aware of governmental regulations, 20 percent admitted to making recommendations that were not consistent with the regulations. </p><p>Clinicians must be aware of and adhere to the strictest legal regulations covering the area in which they practice (and also the areas in which their patients reside, if different from the practice location). It may be helpful for the clinician to point out to the patient that the issue affects public safety as well as patient safety.</p><p class="headingAnchor" id="H1570616449"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112356.html" rel="external">"Society guideline links: Cardiac implantable electronic devices"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15665.html" rel="external">"Patient education: Implantable cardioverter-defibrillators (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16622.html" rel="external">"Patient education: Time to stop driving? (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/3442.html" rel="external">"Patient education: Implantable cardioverter-defibrillators (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3051458"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background </strong>– Data regarding the risks associated with driving with an ICD are primarily retrospective, and there are no trials of driving with or without restrictions. Recommendations are based primarily on expert opinion and public policy. Although restricting driving for a short period of time after implantable cardioverter-defibrillator (ICD) implantation may be necessary, excessive restrictions or a total ban may be unwarranted. (See <a class="local">'Increased risk with driving'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predictors of events </strong>– We consider the following factors when deciding about driving restrictions (see <a class="local">'Predictors of events'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Number of arrhythmic events</p><p class="bulletIndent2"><span class="glyph">•</span>Presence of syncope</p><p class="bulletIndent2"><span class="glyph">•</span>Low left ventricular ejection fraction (LVEF)</p><p class="bulletIndent2"><span class="glyph">•</span>Other cardiac diagnosis </p><p class="bulletIndent2"><span class="glyph">•</span>Treatment with antiarrhythmic drug or catheter ablation treatment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of underlying factors </strong>– All reversible factors that might cause or exacerbate ventricular arrhythmia should be corrected (eg, coronary ischemia, drug toxicity, and electrolyte imbalance, particularly hypokalemia or hypomagnesemia). (See  <a class="medical medical_review" href="/d/html/1040.html" rel="external">"Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis", section on 'Treatment of associated conditions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shared decision-making discussions </strong>– When making therapeutic decisions for life-threatening ventricular arrhythmias, the clinician should make it clear to the patient and family members that driving restrictions may be independent of whether the patient is treated with an ICD or antiarrhythmic drugs as other medical conditions may also contribute to the need to restrict driving. Such discussions can be difficult because of the importance of driving for both independence and quality of life. (See <a class="local">'Recommendations of others and government laws'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Knowledge of legal considerations </strong>– Clinicians must be aware of and adhere to the strictest legal regulations covering the area in which they practice (and also the areas in which their patients reside, if different from the practice location)  (<a class="graphic graphic_table graphicRef120456" href="/d/graphic/120456.html" rel="external">table 1</a>). It may be helpful for the clinician to point out to the patient that the issue affects public safety as well as patient safety. (See <a class="local">'Governmental laws'</a> above.) </p><p></p><p class="headingAnchor" id="H2316839266"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ann Garlitski, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Am Coll Cardiol 1999; 34:1552.</a></li><li><a class="nounderline abstract_t">Grubman EM, Pavri BB, Shipman T, et al. Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators. J Am Coll Cardiol 1998; 32:1056.</a></li><li><a class="nounderline abstract_t">Mitchell LB, Pineda EA, Titus JL, et al. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol 2002; 39:1323.</a></li><li><a class="nounderline abstract_t">Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933.</a></li><li><a class="nounderline abstract_t">Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350:2151.</a></li><li><a class="nounderline abstract_t">Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481.</a></li><li><a class="nounderline abstract_t">Ruwald MH, Okumura K, Kimura T, et al. Syncope in high-risk cardiomyopathy patients with implantable defibrillators: frequency, risk factors, mechanisms, and association with mortality: results from the multicenter automatic defibrillator implantation trial-reduce inappropriate therapy (MADIT-RIT) study. Circulation 2014; 129:545.</a></li><li><a class="nounderline abstract_t">Klein RC, Raitt MH, Wilkoff BL, et al. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol 2003; 14:940.</a></li><li><a class="nounderline abstract_t">Boersma LV, Barr CS, Burke MC, et al. Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm 2017; 14:367.</a></li><li><a class="nounderline abstract_t">Ruwald MH, Ruwald AC, Johansen JB, et al. Temporal Incidence of Appropriate and Inappropriate Therapy and Mortality in Secondary Prevention ICD Patients by Cardiac Diagnosis. JACC Clin Electrophysiol 2021; 7:781.</a></li><li><a class="nounderline abstract_t">Steinberg C, Dognin N, Sodhi A, et al. DREAM-ICD-II Study. Circulation 2022; 145:742.</a></li><li><a class="nounderline abstract_t">Freedberg NA, Hill JN, Fogel RI, et al. Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restrictions. CARE Group. J Am Coll Cardiol 2001; 37:1910.</a></li><li><a class="nounderline abstract_t">Fogoros RN, Elson JJ, Bonnet CA. Actuarial incidence and pattern of occurrence of shocks following implantation of the automatic implantable cardioverter defibrillator. Pacing Clin Electrophysiol 1989; 12:1465.</a></li><li><a class="nounderline abstract_t">Curtis JJ, Walls JT, Boley TM, et al. Time to first pulse after automatic implantable cardioverter defibrillator implantation. Ann Thorac Surg 1992; 53:984.</a></li><li><a class="nounderline abstract_t">Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.</a></li><li><a class="nounderline abstract_t">Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367:2275.</a></li><li><a class="nounderline abstract_t">Steinberg C, Cheung CC, Wan D, et al. Driving Restrictions and Early Arrhythmias in Patients Receiving a Primary-Prevention Implantable Cardioverter-Defibrillator (DREAM-ICD) Study. Can J Cardiol 2020; 36:1269.</a></li><li><a class="nounderline abstract_t">Ruwald AC, Schuger C, Moss AJ, et al. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circ Arrhythm Electrophysiol 2014; 7:785.</a></li><li><a class="nounderline abstract_t">Gold MR, Lambiase PD, El-Chami MF, et al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation 2021; 143:7.</a></li><li><a class="nounderline abstract_t">Larsen GC, Stupey MR, Walance CG, et al. Recurrent cardiac events in survivors of ventricular fibrillation or tachycardia. Implications for driving restrictions. JAMA 1994; 271:1335.</a></li><li><a class="nounderline abstract_t">Levine JH, Mellits ED, Baumgardner RA, et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation 1991; 84:558.</a></li><li><a class="nounderline abstract_t">Whang W, Mittleman MA, Rich DQ, et al. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study. Circulation 2004; 109:1386.</a></li><li><a class="nounderline abstract_t">Bänsch D, Brunn J, Castrucci M, et al. Syncope in patients with an implantable cardioverter-defibrillator: incidence, prediction and implications for driving restrictions. J Am Coll Cardiol 1998; 31:608.</a></li><li><a class="nounderline abstract_t">Kou WH, Calkins H, Lewis RR, et al. Incidence of loss of consciousness during automatic implantable cardioverter-defibrillator shocks. Ann Intern Med 1991; 115:942.</a></li><li><a class="nounderline abstract_t">Strickberger SA, Cantillon CO, Friedman PL. When should patients with lethal ventricular arrhythmia resume driving? An analysis of state regulations and physician practices. Ann Intern Med 1991; 115:560.</a></li><li><a class="nounderline abstract_t">Abello M, Merino JL, Peinado R, et al. Syncope following cardioverter defibrillator implantation in patients with spontaneous syncopal monomorphic ventricular tachycardia. Eur Heart J 2006; 27:89.</a></li><li><a class="nounderline abstract_t">Claro JC, Candia R, Rada G, et al. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev 2015; :CD008093.</a></li><li><a class="nounderline abstract_t">Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007; 357:2657.</a></li><li><a class="nounderline abstract_t">Parkash R, Nault I, Rivard L, et al. Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease). Circ Arrhythm Electrophysiol 2018; 11:e005663.</a></li><li><a class="nounderline abstract_t">Arenal Á, Ávila P, Jiménez-Candil J, et al. Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia. J Am Coll Cardiol 2022; 79:1441.</a></li><li><a class="nounderline abstract_t">Watanabe E, Okajima K, Shimane A, et al. Inappropriate implantable cardioverter defibrillator shocks-incidence, effect, and implications for driver licensing. J Interv Card Electrophysiol 2017; 49:271.</a></li><li><a class="nounderline abstract_t">Albert CM, Rosenthal L, Calkins H, et al. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study. J Am Coll Cardiol 2007; 50:2233.</a></li><li><a class="nounderline abstract_t">Bjerre J, Rosenkranz SH, Schou M, et al. Driving following defibrillator implantation: a nationwide register-linked survey study. Eur Heart J 2021; 42:3529.</a></li><li><a class="nounderline abstract_t">Merchant FM, Hoskins MH, Benser ME, et al. Time Course of Subsequent Shocks After Initial Implantable Cardioverter-Defibrillator Discharge and Implications for Driving Restrictions. JAMA Cardiol 2016; 1:181.</a></li><li><a class="nounderline abstract_t">Akiyama T, Powell JL, Mitchell LB, et al. Resumption of driving after life-threatening ventricular tachyarrhythmia. N Engl J Med 2001; 345:391.</a></li><li><a class="nounderline abstract_t">Assessment of the cardiac patient for fitness to drive. Can J Cardiol 1992; 8:406.</a></li><li><a class="nounderline abstract_t">Epstein AE, Miles WM, Benditt DG, et al. Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. Circulation 1996; 94:1147.</a></li><li><a class="nounderline abstract_t">Jung W, Anderson M, Camm AJ, et al. Recommendations for driving of patients with implantable cardioverter defibrillators. Study Group on 'ICD and Driving' of the Working Groups on Cardiac Pacing and Arrhythmias of the European Society of Cardiology. Eur Heart J 1997; 18:1210.</a></li><li><a class="nounderline abstract_t">Epstein AE, Baessler CA, Curtis AB, et al. Addendum to "Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology": public safety issues in patients with implantable defibrillators: a scientific statement from the American Heart Association and the Heart Rhythm Society. Circulation 2007; 115:1170.</a></li><li><a class="nounderline abstract_t">Bleakley JF, Akiyama T, Canadian Cardiovascular Society, et al. Driving and arrhythmias: implications of new data. Card Electrophysiol Rev 2003; 7:77.</a></li><li><a class="nounderline abstract_t">Kim SG, Hallstrom A, Love JC, et al. Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the Antiarrhythmics Vs Implantable Defibrillators (AVID) trial and nonrandomized registry patients. Am J Cardiol 1997; 80:454.</a></li><li><a class="nounderline abstract_t">Task force members, Vijgen J, Botto G, et al. Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators. Europace 2009; 11:1097.</a></li><li class="breakAll">https://ec.europa.eu/transport/road_safety/sites/roadsafety/files/pdf/behavior/driving_and_cardiovascular_disease_final.pdf (Accessed on February 20, 2019).</li><li><a class="nounderline abstract_t">Mylotte D, Sheahan RG, Nolan PG, et al. The implantable defibrillator and return to operation of vehicles study. Europace 2013; 15:212.</a></li><li><a class="nounderline abstract_t">Curtis AB, Conti JB, Tucker KJ, et al. Motor vehicle accidents in patients with an implantable cardioverter-defibrillator. J Am Coll Cardiol 1995; 26:180.</a></li></ol></div><div id="topicVersionRevision">Topic 948 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10551706" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9768732" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11955850" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8960472" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15152060" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15590950" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24201303" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Syncope in high-risk cardiomyopathy patients with implantable defibrillators: frequency, risk factors, mechanisms, and association with mortality: results from the multicenter automatic defibrillator implantation trial-reduce inappropriate therapy (MADIT-RIT) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12950538" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27890798" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33516705" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Temporal Incidence of Appropriate and Inappropriate Therapy and Mortality in Secondary Prevention ICD Patients by Cardiac Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34913361" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : DREAM-ICD-II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11401131" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restrictions. CARE Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2476775" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Actuarial incidence and pattern of occurrence of shocks following implantation of the automatic implantable cardioverter defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1596160" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Time to first pulse after automatic implantable cardioverter defibrillator implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15659722" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23131066" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reduction in inappropriate therapy and mortality through ICD programming.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32474110" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Driving Restrictions and Early Arrhythmias in Patients Receiving a Primary-Prevention Implantable Cardioverter-Defibrillator (DREAM-ICD) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25136077" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33073614" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8158818" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recurrent cardiac events in survivors of ventricular fibrillation or tachycardia. Implications for driving restrictions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1860200" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993132" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9502643" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Syncope in patients with an implantable cardioverter-defibrillator: incidence, prediction and implications for driving restrictions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1952491" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Incidence of loss of consciousness during automatic implantable cardioverter-defibrillator shocks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1883126" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : When should patients with lethal ventricular arrhythmia resume driving? An analysis of state regulations and physician practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16183691" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Syncope following cardioverter defibrillator implantation in patients with spontaneous syncopal monomorphic ventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26646017" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18160685" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prophylactic catheter ablation for the prevention of defibrillator therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29305400" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35422240" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28730420" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Inappropriate implantable cardioverter defibrillator shocks-incidence, effect, and implications for driver licensing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18061071" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33954626" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Driving following defibrillator implantation: a nationwide register-linked survey study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27437889" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Time Course of Subsequent Shocks After Initial Implantable Cardioverter-Defibrillator Discharge and Implications for Driving Restrictions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11496849" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Resumption of driving after life-threatening ventricular tachyarrhythmia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1617524" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Assessment of the cardiac patient for fitness to drive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8790068" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9458413" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Recommendations for driving of patients with implantable cardioverter defibrillators. Study Group on 'ICD and Driving' of the Working Groups on Cardiac Pacing and Arrhythmias of the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287391" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Addendum to "Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology": public safety issues in patients with implantable defibrillators: a scientific statement from the American Heart Association and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12766524" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Driving and arrhythmias: implications of new data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9285657" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the Antiarrhythmics Vs Implantable Defibrillators (AVID) trial and nonrandomized registry patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19525498" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19525498" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22968849" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The implantable defibrillator and return to operation of vehicles study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797749" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Motor vehicle accidents in patients with an implantable cardioverter-defibrillator.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
